Who gains from the relentless rise in IP applications?

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Who gains from the relentless rise in IP applications?

WIPO has just revealed its annual report on IP indicators, filled with superlatives about fastest rates of growth and record numbers of filings. After a short-term drop following the lowest point of the global financial crisis, it seems as though the steady uptick in global IP applications continues

But should we celebrate or be concerned about the statistics?

Take China. WIPO says that last year, for the first time, residents of China accounted for the largest number of patents filed throughout the world. The country’s IP office, SIPO, received more applications than any other IP office.

It’s not just in the patent field where China dominates. Last year, residents of China filed trade mark applications with more than 1.5 million class counts – more than three times as many as the next biggest class filer, the US.

So how should we interpret the statistics? One interpretation is that they signal a real change in levels of Chinese innovation and brand creation. Another is that they represent a flood of applications for utility model patents and bad faith trade mark filings. (Chinese companies are far more likely that foreign ones to apply for lower-value utility models rather than invention patents in China – a phenomenon that the government is seeking to change. High levels of trade mark squatting have exasperated foreign companies entering the Chinese market).

The answer, of course, is probably a bit of both.

The majority of practitioners and IP professionals understand that global patent filing growth rates of 9%-plus and a 6% rise on trade mark class counts may not be unqualified good news: the pressure on IP offices, leading to patent thickets and overcrowded registers and the high cost of challenging duff patents and other IP rights? are just a few of the potential problems.

But while there might be agreement that the relentless rise in IP applications is not necessarily a Good Thing at the aggregate level, is there an agreement about what should be done about it?

One option, or course, is to do nothing. Another is for IP lawmakers and examiners to make it tougher to obtain IP rights. Yet another is for IP attorneys to discourage their clients from adding to the pile of weak applications. After all, isn’t improving the system better for all IP owners and users in the long run? While the season may be apt for metaphors about turkeys and Christmas, isn’t that something the profession should consider? Do you – or should you – tell clients not to apply for IP rights? Do let us know.

more from across site and SHARED ros bottom lb

More from across our site

News of Avanci hiring a senior vice president and the EPO teaming up with a French AI startup were also among the top talking points
Explosm, the independent Texas studio behind the hit webcomic Cyanide & Happiness, partnered with Temu’s IP protection team to combat counterfeiters infringing on its brand
The latest in a dispute over juicing machines, and a shakeup in judicial compositions were also among the top developments
Patent partner Robert Hollingshead explains why the firm remains committed to Japan despite several US firms exiting the Japanese and greater Asia market
Emma Green, partner at Bird & Bird, shares why the Iceland v Iceland dispute could prompt businesses and lawyers to think differently about brand enforcement
Attain IP, developed by two UK patent lawyers, will meet ‘forensic’ needs of patent attorneys by showing a verifiable reasoning chain, according to its co-founders
The High Court of Australia has allowed a fashion designer to retain her registered ‘Katie Perry’ trademark for clothing
Sim & San secured the win for Dr. Reddy’s, which will allow the pharma company to manufacture and export semaglutide, the active ingredient in Ozempic
Lucas Amodio joins our ‘Five minutes with’ series to discuss artificial intelligence systems and patent law
The Americas research cycle has commenced, so don't miss the opportunity to submit your work
Gift this article